Refine
Has Fulltext
- yes (188)
Is part of the Bibliography
- yes (188) (remove)
Year of publication
Document Type
- Journal article (188) (remove)
Language
- English (188) (remove)
Keywords
- CXCR4 (7)
- T cells (6)
- apoptosis (6)
- glioblastoma (6)
- immunohistochemistry (6)
- lymphoma (6)
- multiple myeloma (6)
- B cells (5)
- astrocytoma (5)
- cancer (5)
- gene expression (5)
- glioblastoma multiforme (5)
- recurrence (5)
- NFATc1 (4)
- brain (4)
- breast cancer (4)
- chemokine receptor (4)
- expression (4)
- forensic neuropathology (4)
- mRNA (4)
- machine learning (4)
- metastasis (4)
- prognosis (4)
- relapse (4)
- therapy (4)
- EGFR (3)
- Hodgkin lymphoma (3)
- MYC (3)
- NRF2 (3)
- PET/CT (3)
- biomarker (3)
- cerebrospinal fluid (3)
- forensic neurotraumatology (3)
- gene regulation (3)
- glioma (3)
- melanoma (3)
- neuronal differentiation (3)
- poor prognosis (3)
- positron emission tomography (3)
- protein (3)
- surgical oncology (3)
- ATF4 (2)
- BCL6 (2)
- CD30 (2)
- Cushing’s syndrome (2)
- DLBCL (2)
- EMT (2)
- Expression (2)
- FGFR (2)
- Glioblastoma (2)
- HNSCC (2)
- KEAP1 (2)
- MPS1 (2)
- Medizin (2)
- NAFLD (2)
- NASH (2)
- NFAT (2)
- NSCLC (2)
- Nfatc1 (2)
- PET (2)
- PTCL (2)
- Rhabdomyosarcoma (2)
- T-cell lymphoma (2)
- USP28 (2)
- adrenocortical carcinoma (2)
- alloreactive T cells (2)
- amplicon sequencing (2)
- angiogenesis (2)
- animal model (2)
- brain tumor (2)
- cancer stem cells (2)
- cancers and neoplasms (2)
- carcinomas (2)
- case report (2)
- cell staining (2)
- cell-cycle arrest (2)
- cytotoxic T cells (2)
- development (2)
- discriminant analysis (2)
- endothelial cells (2)
- enzyme-linked immunoassays (2)
- flow cytometry (2)
- gene (2)
- germinal center (2)
- imaging (2)
- immune response (2)
- immunohistochemistry techniques (2)
- in vivo imaging (2)
- inflammation (2)
- keratinocytes (2)
- kidneys (2)
- low-grade glioma (2)
- lung cancer (2)
- malignant tumors (2)
- messenger RNA (2)
- miRNA (2)
- mice (2)
- microenvironment (2)
- molecular diagnostics (2)
- molecular imaging (2)
- mouse models (2)
- mutations (2)
- neuroinflammation (2)
- obesity (2)
- organoids (2)
- plasma cells (2)
- positron emission tomography/computed tomography (2)
- postnatal development (2)
- principal component analysis (2)
- proteomics (2)
- radiotherapy (2)
- rat (2)
- receptor tyrosine kinases (2)
- regression analysis (2)
- survival (2)
- temozolomide (2)
- thymus (2)
- transcription (2)
- tumor microenvironment (2)
- vestibular schwannoma (2)
- vitamin D (2)
- 3D ex vivo models (1)
- 3D lung tumor tissue models (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- AD-AID (1)
- ADAM9 (1)
- ADP-ribosylation toxins (1)
- AICDA (1)
- AID-ΔE4a (1)
- AKT-signaling (1)
- ALCL (1)
- ALK-1 (1)
- AOM/DSS (1)
- ATG7 (1)
- ATM (1)
- Activation (1)
- Adamantiades-Behçet disease (1)
- Adult (1)
- Alpha therapy (1)
- Antibodies (1)
- Antiparanodal Autoantibodies (1)
- Aphthae (1)
- Autoimmune diseases (1)
- B cell malignancies (1)
- B-MYB (1)
- B-cell lymphoma (1)
- B-cells (1)
- BIRC7 (1)
- Barrett-Ösophagus (1)
- Behçet’s disease (1)
- Bevacizumab (1)
- Bioluminescence imaging (1)
- Biomarker (1)
- Bone chips (1)
- Bone marrow cells (1)
- Bone marrow transplantantation (1)
- Bone marrow transplantation (1)
- Braak (1)
- Breast-cancer (1)
- Bruton Tyrosine Kinase (1)
- B‐cell lymphoma (1)
- C-Myc (1)
- C3 (1)
- CD/metabolism (1)
- CD117 (1)
- CD133 (1)
- CD274 (1)
- CD319 (1)
- CD40 ligand (1)
- CD56 (1)
- CD9 (1)
- CHAC1 (1)
- CK5 (1)
- COVID-19 (1)
- CRC (1)
- CRISPR-Cas9 (1)
- CRISPR/Cas9 (1)
- CS1 (1)
- CSF (1)
- CTNNB1 (1)
- CX5461 (1)
- CXCL5 (1)
- CXCL8 (1)
- CXCR2 (1)
- CXCR4/SDF-1 (1)
- CXCR7 (1)
- CYP24A1 (1)
- CYP2W1 (1)
- Cancer (1)
- Cancer genetics (1)
- Cancer treatment (1)
- Chains (1)
- Chemotherapy (1)
- Childhood (1)
- Cisplatin (1)
- Clonality (1)
- Cushings syndrome (1)
- Cushing’s disease (1)
- DEL(5Q) (1)
- DHAP (1)
- DNA hypermethylation (1)
- DNA methylation (1)
- DNA-PK (1)
- DOTATOC (1)
- DT40 cells (1)
- DWI (1)
- Defined burkitts lymphoma (1)
- Delta Repertoire (1)
- Design (1)
- Diabetes mellitus (1)
- E-cadherin (1)
- EAHP/SH bone marrow workshop (1)
- EBER in situ hybridization (1)
- EBV (1)
- EGF (1)
- ERM proteins (1)
- EZH1 (1)
- EZH2 (1)
- Epidemiological study (1)
- Epitope (1)
- Epstein-Barr virus (1)
- Extraocular eye muscles (1)
- F-19 MRI (1)
- FADD (1)
- FARS1 (1)
- FDG PET/CT (1)
- FFPE (1)
- FGF-pathway (1)
- FINCA (1)
- FLT-PET (1)
- FTIR spectroscopy (1)
- Factor receptor (1)
- Fibrin glue (1)
- Frequency (1)
- GFAP (1)
- GIST (1)
- GLP-1 (1)
- GSH (1)
- Gene-expression (1)
- Genitoanal region (1)
- Genome wide analysis (1)
- Glioma stem cells (1)
- Graft-versus-leukemia (1)
- GvHD (1)
- H3K27me3 (1)
- HD (1)
- HER2 conversion (1)
- HER2 targeted therapy (1)
- HER2-low (1)
- HNSC (1)
- HSC (1)
- Hans algorithm (1)
- Head (1)
- Head and neck cancers (1)
- High-resolution (1)
- Histone deacetylase inhibition (1)
- Hsp90 (1)
- Hypercortisolism (1)
- IDH (1)
- IDH1/2 (1)
- IFN (1)
- IFN-γ (1)
- IL-10 (1)
- IL-17 (1)
- IL-2 (1)
- IR (1)
- IRF4 (1)
- Ibrutinib (1)
- Images (1)
- Immunosuppression (1)
- Immunotherapy (1)
- In-vivo (1)
- Inflammation (1)
- Intestinal Intraepithelial Lymphocy (1)
- Iron-oxide (1)
- Irradiation (1)
- JAK inhibitor (1)
- JUN (1)
- KIT (1)
- KRAS (1)
- KRAS biomarker signatures (1)
- Kaposi sarcoma (1)
- Kidney cancer (1)
- Krebs (1)
- LESA (1)
- LITAF (1)
- Lateral suboccipital craniectomy (1)
- Lesions (1)
- Ligand (1)
- Lipom (1)
- Lung-cancer (1)
- Lymph2Cx assay (1)
- Lymphoma (1)
- Lymphomas (1)
- MDS (1)
- MEK/ERK-signaling (1)
- MGMT (1)
- MGMT promoter methylation (1)
- MITF-low (1)
- MIZ1 (1)
- MRSA (1)
- MTB (1)
- MTCH2 (1)
- MTX (1)
- Malignancies (1)
- Mantle cell lymphoma (1)
- Medical research (1)
- Merlin (1)
- Metastases (1)
- Microarray (1)
- Molecular pathogenesis (1)
- Multiple Myeloma (1)
- Myb-MuvB (1)
- Myeloma cells (1)
- Myelomas (1)
- NEC (1)
- NET (1)
- NF-KAPPA-B (1)
- NF-\(\kappa\)B pathway (1)
- NFE2L2 (1)
- NGS (1)
- NHLRC2 (1)
- NLPHL (1)
- NR3C1 (1)
- NSG (1)
- NSG-SGM3 (1)
- Nestin (1)
- Nodo-parandopathy (1)
- Nrf2 (1)
- Nuclear expression (1)
- OBF-1 OCA-B (1)
- OCT-1-deficient mice (1)
- OncotypeDX\(^{®}\) (1)
- Organoids (1)
- Osteogeneration (1)
- Osteopontin (1)
- PAI-1 (1)
- PCDHGC3 (1)
- PCI-32765 (1)
- PD-L1 (1)
- PI3K (1)
- PLAG1 rearrangement (1)
- PRRT (1)
- PTEN (1)
- Parkinson (1)
- Parkinsons disease (1)
- Parkinson’s disease (1)
- Particles (1)
- Pathway (1)
- Pentixafor (1)
- Positron emission tomography (1)
- Positronen-Emissions-Tomografie (1)
- Pou2af1 (1)
- Profiling (1)
- Prognosis (1)
- Proliferation (1)
- Promoter (1)
- R-CHOP (1)
- RCC (1)
- RNA Expression (1)
- RNA probe (1)
- RNAPOL1 (1)
- RNAScope (1)
- RYGB (1)
- Rats (1)
- Regulatory-cells (1)
- Renal cell carcinoma (1)
- Rheumatoid arthritis (1)
- Rho-GTPases (1)
- Rituximab plus (1)
- Riutximab (1)
- SARS-CoV-2 (1)
- SB332235 (1)
- SGN-35 (1)
- SLC7A11 (1)
- SOAT1 (1)
- SSTR (1)
- Soft-tissue infection (1)
- Sox9 (1)
- SphK1 (1)
- Spinal dissemination (1)
- Spindle cell (1)
- Spleen (1)
- Sprue (1)
- Staphylococcus aureus (1)
- Staphylococcus aureus immune response (1)
- Sunitinib (1)
- Suppression (1)
- Surgery (1)
- Survival (1)
- T cell differentiation (1)
- T cell receptors (1)
- T(H)17 cells (1)
- T-cell non-Hodgkin's lymphomas (1)
- T-cell transfer (1)
- T-follicular regulatory cell (1)
- TCR signaling cascade (1)
- TGF-alpha (1)
- TP53 (1)
- TP53 mutations (1)
- TTK (1)
- T\(_{reg}\) and Foxp3 (1)
- Targeted Therapies (1)
- Targets (1)
- Temozolomide (1)
- Th17 (1)
- Tracking (1)
- Transcription-factor (1)
- Translational research (1)
- Tregs (1)
- Tumor Microenvironment (1)
- Tumor Treating Fields (TTFields) (1)
- Tumor-necrosis-factor (1)
- Tumour markers (1)
- Tyrosine kinase inhibition (1)
- UMAP (1)
- USP8 (1)
- USP9X (1)
- Usage (1)
- Uveitis (1)
- VDR (1)
- WNT signaling (1)
- WTAP (1)
- Waldeyer’s tonsillar ring (1)
- Wilms tumour (1)
- XIAP (1)
- YAP (1)
- [18F]FDG-PET-CT (1)
- [18F]Fluorodeoxythymidine (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{68}\)Ga-Pentixafor (1)
- abdominal lymph node metastases (1)
- abnormalities (1)
- actin (1)
- actin filament (1)
- actin filaments (1)
- activation (1)
- acute graft-versus host disease (1)
- acute graft-versus-host disease (1)
- acute lymphoblastic leukemia (1)
- acute lymphocytic leukaemia (1)
- acute myeloid leukaemia (1)
- acute myeloid leukemia (1)
- adenomas (1)
- adenosine kinase (1)
- adhesion (1)
- adrenal glands (1)
- adrenal tumor (1)
- adrenocortical (1)
- adrenocortical cancer (1)
- adrenocortical tissues (1)
- adrenocortical tumors (1)
- aggressive B‐cell lymphoma (1)
- allergy (1)
- alternative splicing (1)
- aluminum granuloma (1)
- aminoacyl‐tRNA synthetases (1)
- amplifications (1)
- amyloidoma (1)
- amyloidosis (1)
- anaplasia (1)
- anaplastic large cell lymphoma (1)
- anaplastic large cell lymphoma (ALCL) (1)
- anaplastic medulloblastoma (1)
- annecin-V (1)
- anti-CD30 drug conjugate (1)
- anti-inflammatory cytokines (1)
- antibodies (1)
- antigen (1)
- antigen loss (1)
- antigens (1)
- antioxidant function (1)
- aortic adventitia (1)
- apoptosis, Myc (1)
- arteriovenous loop (1)
- atopic dermatitis (1)
- atrial natriuretic peptide (1)
- aurora kinase A polymorphism (1)
- aurorakinase B (1)
- autoantibodies (1)
- autoantigen (1)
- autoimmune disease (1)
- autologous transplantation (1)
- autophagy (1)
- axonally transported proteins (1)
- azacitidine (1)
- bacterial toxins (1)
- behavior (1)
- benige tumor (1)
- beta-catenin (1)
- binding (1)
- binding proteins (1)
- biofluid (1)
- bioinformatic clustering (1)
- biological sciences (1)
- biomarker prediction (1)
- biosynthesis (1)
- blood–brain barrier (1)
- bone disease (1)
- bone marrow biopsy (1)
- bone marrow cells (1)
- bone marrow–spleen–liver large B‐cell lymphoma (1)
- bone metastasis (1)
- boolean in silico models (1)
- botulinum C2 toxin (1)
- buparlisib (1)
- c-MYC (1)
- c-myc (1)
- cadaver multiorgan preservation (1)
- cancer care (1)
- cancer detection (1)
- cancer diagnosis (1)
- cancer metabolism (1)
- cancer of unknown primary (CUP) (1)
- cancer treatment (1)
- carcinogenesis (1)
- carcinoma (1)
- carcinoma metastases to pancreas (1)
- cardiac transplantation (1)
- cardiomyocyte proliferation (1)
- caspase-3 (1)
- catenin (1)
- caveolin-1 (1)
- cell binding (1)
- cell cycle and cell division (1)
- cell death (1)
- cell of origin (1)
- cells (1)
- cellular uptake (1)
- cerebellum (1)
- cerebral cortex (1)
- cerebropulmonary disease (1)
- cetuximab (1)
- checkpoint inhibition (1)
- chemokine (1)
- chemokine receptor-4 (1)
- childhood interstitial lung disease (1)
- children (1)
- children´s interstitial lung disease (chILD) lipoid pneumonia (1)
- cholesterol pneumonia (1)
- cholesterol pneumonitis (1)
- chromatin (1)
- chromosomal aberration (1)
- chromosomes (1)
- chronic IBD model (1)
- chronophin (1)
- classical Hodgkin lymphoma (1)
- classification (1)
- cleavage (1)
- clostridium botulinum (1)
- coactivator OBF-1 (1)
- coated vesicles (1)
- cofilin (1)
- combined immunodeficiency (1)
- combined therapy (1)
- comparative genomic hybridization (1)
- complement system (1)
- complex (1)
- confocal Raman imaging (1)
- consensus DNA (1)
- cross-priming (1)
- cutaneous T-cell-lymphoma (1)
- cycle (1)
- cyclophsophamide (1)
- cyclosporine A (1)
- cytotoxicity (1)
- damage (1)
- damage responses (1)
- deformation (1)
- deletions (1)
- diagnostics (1)
- diffuse large B-cell lymphoma (1)
- diffuse large B‐cell lymphoma (1)
- disease (1)
- distinct (1)
- down regulation (1)
- drug abuse (1)
- drug resistance (1)
- drug therapy (1)
- early breast cancer (1)
- echocardiography (1)
- ectopic lymphoid follicle (1)
- effector Treg (eTreg) (1)
- ejection fraction (1)
- embryonic lethality (1)
- encephalitis lethargica (1)
- enhancer (1)
- ephitelial cells (1)
- epigenetics (1)
- epithelial markers (1)
- epithelium (1)
- extracorporeal membrane oxygenation (1)
- extramedullary disease (1)
- features (1)
- ferroptosis (1)
- fibroblast activation protein (1)
- fixation (1)
- fluorescence in situ hybridisation (1)
- follicular T helper cells (1)
- follicular lymphoma (1)
- forecasting (1)
- formalin (1)
- functional characterization (1)
- gRNA-only (1)
- gastric bypass (1)
- gastrointestinal infections (1)
- gefitinib (1)
- genetic loci (1)
- genomic aberrations (1)
- germinal center formation (1)
- germline mutation (1)
- gesolin function (1)
- glioblastoma multiforme (GBM) (1)
- glucocorticoid excess (1)
- glutaminase inhibition (1)
- goldfish optic nerve (1)
- grade 3B (1)
- group 3 (1)
- growth (1)
- growth pattern (1)
- growth patterns (1)
- growth-associated protein (1)
- gut–liver axis (1)
- head and neck cancer (1)
- heart (1)
- heart failure (1)
- helper T cells (1)
- helper T-cells (1)
- hematopoiesis (1)
- hematopoietic stem cells (1)
- hemophagocytosis (1)
- hepcidin (1)
- high numbers (1)
- high-dose chemotherapy (1)
- high-resolution analysis (1)
- high-risk Prostate Cancer (1)
- high‐grade B‐cell lymphoma (1)
- hippocampal stem cells (1)
- hnRNP K (1)
- hormones (1)
- human (1)
- human brain (1)
- human cerebral endothelial cells (1)
- human genome (1)
- humanized hemato-lymphoid mice (1)
- humanized mice (1)
- humoral immunity (1)
- hyper-IgM syndrome type 2 (HIGM2) (1)
- hypercortisolism (1)
- iiron transporter (1)
- immune cells (1)
- immune check inhibitor (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitor (ICI) (1)
- immune evasion (1)
- immune infiltration (1)
- immune system (1)
- immunity (1)
- immunocytochemistry (1)
- immunofuorescence double staining (1)
- immunoglobulin promoters (1)
- immunology and microbiology section (1)
- immunotherapeutics (1)
- immunotherapy (1)
- in silico analysis (1)
- in-vitro (1)
- in-vivo (1)
- independent predictor (1)
- induction (1)
- inflammation-induced tissue demage (1)
- integrated stress response (1)
- integrin (1)
- interleukin-8 (1)
- interleukins (1)
- intestine (1)
- intraosseous (1)
- intravascular large B‐cell lymphoma (1)
- invasion (1)
- involvement (1)
- iron in parkinsonism (1)
- iron model (1)
- iron pathology (1)
- karyotype (1)
- kidney cancer (1)
- kinase (1)
- kinases (1)
- knock down (1)
- large cell transformation (1)
- latency type (1)
- lesions (1)
- leukemia (1)
- lichen planus (1)
- lineage (1)
- lineage differentiation (1)
- lipid droplets (1)
- lipids (1)
- lipoblastoma (1)
- lipoid pneumonitis (1)
- liquid biopsy (1)
- liraglutide (1)
- livin (1)
- lung fibrosis (1)
- lymph node stromal cells (1)
- lymph node transplantation (1)
- lymphocyte activation (1)
- lymphocyte differentiation (1)
- lymphocytes (1)
- lymphohistiocytosis (1)
- lymphoid aggregate (1)
- lymphoid hyperplasia (1)
- lymphoid-tissue (1)
- lymphoid-tissue lymphomas (1)
- mRNA expression (1)
- mTOR (1)
- major histocompatibility complex (1)
- malignancies (1)
- malt lymphoma (1)
- mammalian cells (1)
- mandible (1)
- mantel cell lymphoma (1)
- mantle cell lymphoma (1)
- marcophages (1)
- marrow transplantation (1)
- mass cytometry (1)
- mast cells (1)
- mastocytosis (1)
- measles virus (1)
- medical research (1)
- medicine (1)
- membrane topology (1)
- membrane translocation (1)
- memory B cells (1)
- meningeal inflammation (1)
- meningioma (1)
- mesenchymal markers (1)
- mesenteric lymph node (1)
- mesentery (1)
- messenger-RNA transport (1)
- metabolism (1)
- metagenomics (1)
- metastasis-associated in colon cancer 1 (MACC1) (1)
- methylation (1)
- miR-126 (1)
- miR-21 (1)
- microRNA-221 (1)
- microglia (1)
- microvessel permeability (1)
- mild hypothermia (1)
- mitochondrial DNA (1)
- mitosis (1)
- mitotane (1)
- mitotic genes (1)
- molecular subtypes (1)
- monoclonal antibody (1)
- mouse model (1)
- mtDNA (1)
- multifocal growth (1)
- multigene-array (1)
- multiple sclerosis (1)
- multivariate data analysis (1)
- multi‐organ disease (1)
- murine homolog (1)
- mutant p53 (1)
- mutation (1)
- mutational targeting (1)
- myasthenia (1)
- myasthenia gravis (1)
- mycosis fungoides (1)
- naive T-cell gene editing (1)
- nephroblastoma (1)
- nervous system (1)
- network (1)
- neurodegeneration (1)
- neurodegenerative disease (1)
- neuroendocrine tumor (1)
- neuromelanin (1)
- neurooncology (1)
- neuropathology (1)
- neuroscience (1)
- neurotoxicity (1)
- neurovascular unit (1)
- neutral loss (1)
- next generation sequencing (1)
- niche (1)
- nodular lymphcyte (1)
- non-small cell lung cancer (1)
- noncoding RNAs (1)
- normal adrenal glands (1)
- notch signaling (1)
- obinutuzumab (1)
- olfactory bulb (1)
- organotypic hippocampal slice cultures (OHSC) (1)
- orthotopic xenograft (1)
- outcomes research (1)
- outreach (1)
- oxidative stress (1)
- p53 (1)
- p53 expression (1)
- p53-dependent apoptosis (1)
- p53-inducible regulator (1)
- pFADD (1)
- pan-RCC (1)
- pancreatic cancer (1)
- panel sequencing (1)
- panel-sequencing (1)
- panniculitis (1)
- parathyroid carcinoma (1)
- parkinson’s disease (1)
- pathogenesis (1)
- pathology (1)
- pathway (1)
- patient access (1)
- patient survival (1)
- pediatric (1)
- pediatric lymphoma (1)
- pembrolizumab (1)
- peptide receptor radionuclide therapy (1)
- peptide receptor radionuclide therapy (PRRT) (1)
- peptide tyrosine tyrosine (PYY) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- peripheral T-cell (1)
- phosphatase 2A (1)
- phospholipase A(2) (1)
- plasmablasts (1)
- pleural mesothelioma (1)
- post-mortem heart recovery (1)
- postencephalitic parkinsonism (1)
- precision oncology (1)
- prediction (1)
- primary bone marrow presentation (1)
- primary cell culture (1)
- primary cutaneous follicular B-cell lymphoma (1)
- pro-inflammatory cytokines (1)
- prognostic factor (1)
- prognostic marker (1)
- prognostic value (1)
- progressive multiple sclerosis (1)
- prostate cancer (1)
- protein and mRNA expression (1)
- proteins (1)
- pseudocarcinomatous hyperplasia (1)
- pseudolymphoma (1)
- psoas muscle (1)
- psoriasis (1)
- radiation (1)
- radiation-induced migration (1)
- raman spectroscopy (1)
- rare SNP (1)
- real world data (1)
- recurrence-free survival (1)
- refractory/relapsed lymphoma (1)
- regional development (1)
- regulatory T cells (1)
- regulatory T-cells (1)
- renal cancer (1)
- renal cell carcinoma (1)
- repeated surgery (1)
- resistance (1)
- restoration (1)
- retroperitoneal tumor (1)
- reverse transcriptase-polymerase chain reaction (1)
- ribosome (1)
- ribosyltransferase (1)
- roquin (1)
- salivary gland neoplasia (1)
- salivary gland tumor (1)
- salivary gland tumors (1)
- salivary glands (1)
- scoring system (1)
- seminoma (1)
- senescence (1)
- serum (1)
- signal transduction (1)
- slice culture (1)
- somatic hypermutation (1)
- somatic mutations (1)
- spinal-cord-injury (1)
- splice variant (1)
- squamous tumors (1)
- staphylococcal abscess (1)
- stem cell transplantation (1)
- stem-cells (1)
- stemness (1)
- subventricular zone (1)
- suppression (1)
- suppressor (1)
- surgery (1)
- surgical and invasive medical procedures (1)
- surgical treatment (1)
- systemic sclerosis (1)
- t-SNE (1)
- target (1)
- target validation (1)
- targeted (1)
- targeted combination therapy (1)
- targeted sequencing (1)
- targeted therapies (1)
- targeted therapy (1)
- tauopathy (1)
- tetraspanin (1)
- tetraspanin protein (1)
- theranostics (1)
- therapeutic target (1)
- therapy response (1)
- thiol starvation (1)
- thymic carcinoma (1)
- thymic epithelial tumor (1)
- thymitis (1)
- thymocytes (1)
- thymoma (1)
- tissue preparation (1)
- tofacitinib (1)
- transcript (1)
- transcription factor FOXP1 (1)
- transcription factors (1)
- transcriptional repression (1)
- transcriptome (1)
- transcriptomic analysis (1)
- transformation (1)
- translocation (1)
- transplantation (1)
- trastuzumab (1)
- trastuzumab deruxtecan (1)
- treatment regimens (1)
- treg cells (1)
- triple-negative breast cancer (1)
- tumor heterogeneity (1)
- tumor immunology (1)
- tumor slice cultures (1)
- tumor spheroids (1)
- tumor vaccination (1)
- tumor-vessel wall-interface model (1)
- tumorigenesis (1)
- tumormicroenvironment (1)
- tumors (1)
- tumour heterogeneity (1)
- tyrosine kinase inhibitor (TKI) (1)
- uPA (1)
- ubiquitin (1)
- unsupervised clustering (1)
- up regulation (1)
- vascular wall stem and progenitor cells (1)
- vascularization model (1)
- vasculogenesis (1)
- vemurafenib (1)
- venetoclax (1)
- virus–iron interaction (1)
- visual clustering (1)
- vitamin D receptor (1)
- vitamin metabolism (1)
- von Economo (1)
- whole-exome sequencing (1)
- ɑ-Synuclein and iron (1)
- α-synuclein-specific T cells (1)
Institute
- Pathologisches Institut (188) (remove)
Sonstige beteiligte Institutionen
- Center for Interdisciplinary Clinical Research, Würzburg University, Würzburg, Germany (1)
- Department of Paediatric Radiology, Institute of Diagnostic and Interventional Radiology, Josef-Schneider-Straße 2, Wuerzburg 97080, Germany (1)
- IZKF Nachwuchsgruppe Geweberegeneration für muskuloskelettale Erkrankungen (1)
- Lehrstuhl für Regeneration Muskuloskelettaler Gewebe (1)
- Muskuloskelettales Centrum Würzburg (MCW) (1)
We herein report the case of a 73‐year‐old male patient who was diagnosed with leukemic non‐nodal MCL. This patient had received six cycles of bendamustine, which resulted in a transient remission, and a second‐line therapy with ibrutinib, which unfortunately failed to induce remission. We started a treatment with single‐agent obinutuzumab at a dose of 20 mg on day 1, 50 mg on day 2‐4, 330 mg on day 5, and 1000 mg on day 6. The laboratory analysis showed a rapid decrease of leukocyte count. Four weeks later, we repeated the treatment with obinutuzumab at a dose of 1000 mg q4w and started a therapy with venetoclax at a dose of 400 mg qd, which could be increased to 800 mg qd from the third cycle. This combination therapy was well tolerated. The patient achieved a complete remission (CR) after three cycles of obinutuzumab and venetoclax. To date, the patient has a progression‐free survival of 17 months under ongoing obinutuzumab maintenance q4w. This is the first report about obinutuzumab and venetoclax induced CR in rituximab‐intolerant patient with an ibrutinib‐resistant MCL. This case suggests that obinutuzumab‐ and venetoclax‐based combination therapy might be salvage therapy in patients with ibrutinib‐resistant MCL.
The subclassification of diffuse large B-cell lymphoma (DLBCL) into germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes has become mandatory in the 2017 update of the WHO classification of lymphoid neoplasms and will continue to be used in the WHO 5\(^{th}\) edition. The RNA-based Lymph2Cx assay has been validated as a reliable surrogate of high-throughput gene expression profiling assays for distinguishing between GCB and ABC DLBCL and provides reliable results from formalin-fixed, paraffin-embedded (FFPE) material. This test has been previously used in clinical trials, but experience from real-world routine application is rare. We routinely applied the Lymph2Cx assay to day-to-day diagnostics on a series of 147 aggressive B-cell lymphoma cases and correlated our results with the immunohistochemical subclassification using the Hans algorithm and fluorescence in situ hybridization findings using break-apart probes for MYC, BCL2, and BCL6. The routine use of the Lymph2Cx assay had a high technical success rate (94.6%) with a low rate of failure due to poor material and/or RNA quality. The Lymph2Cx assay was discordant with the Hans algorithm in 18% (23 of 128 cases). Discordant cases were mainly classified as GCB by the Hans algorithm and as ABC by Lymph2Cx (n = 11, 8.6%). Only 5 cases (3.9%) were classified as non-GCB by the Hans algorithm and as GCB by Lymph2Cx. Additionally, 5.5% of cases (n = 7) were left unclassified by Lymph2Cx, whereas they were defined as GCB (n = 4) or non-GCB (n = 3) by the Hans algorithm. Our data support the routine applicability of the Lymph2Cx assay.
CD9 is the best-studied member of the tetraspanin family of transmembrane proteins. It is involved in various fundamental cellular processes and its altered expression is a characteristic of malignant cells of different origins. Despite numerous investigations confirming its fundamental role, the heterogeneity of CD9 or other tetraspanin proteins was considered only to be caused by posttranslational modification, rather than alternative splicing. Here we describe the first identification of CD9 transcript variants expressed by cell lines derived from fetal rat brain cells. Variant mRNA-B lacks a potential translation initiation codon in the alternative exon 1 and seems to be characteristic of the tumorigenic BT cell lines. In contrast, variant mRNA-C can be translated from a functional initiation codon located in its extended exon 2, and substantial amounts of this form detected in various tissues suggest a contribution to CD9 functions. From the alternative sequence of variant C, a different membrane topology ( 5 transmembrane domains) and a deviating spectrum of functions can be expected.
Background: Primary cutaneous follicular B-cell lymphoma (PCFBCL) represents an indolent subtype of Non-Hodgkin’s lymphomas, being clinically characterized by slowly growing tumors of the skin and common cutaneous relapses, while only exhibiting a low propensity for systemic dissemination or fatal outcome. Up to now, only few studies have investigated underlying molecular alterations of PCFBCL with respect to somatic mutations. Objectives: Our aim was to gain deeper insight into the pathogenesis of PCFBCL and to delineate discriminatory molecular features of this lymphoma subtype. Methods: We performed hybridization-based panel sequencing of 40 lymphoma-associated genes of 10 cases of well-characterized PCFBCL. In addition, we included two further ambiguous cases of atypical B-cell-rich lymphoid infiltrate/B-cell lymphoma of the skin for which definite subtype attribution had not been possible by routine investigations. Results: In 10 out of 12 analyzed cases, we identified genetic alterations within 15 of the selected 40 target genes. The most frequently detected alterations in PCFBCL affected the TNFRSF14, CREBBP, STAT6 and TP53 genes. Our analysis unrevealed novel mutations of the BCL2 gene in PCFBCL. All patients exhibited an indolent clinical course. Both the included arbitrary cases of atypical B-cell-rich cutaneous infiltrates showed somatic mutations within the FAS gene. As these mutations have previously been designated as subtype-specific recurrent alterations in primary cutaneous marginal zone lymphoma (PCMZL), we finally favored the diagnosis of PCMZL in these two cases based on these molecular findings. Conclusions: To conclude, our molecular data support that PCFBCL shows distinct somatic mutations which may aid to differentiate PCFBCL from pseudo-lymphoma as well as from other indolent and aggressive cutaneous B-cell lymphomas. While the detected genetic alterations of PCFBCL did not turn out to harbor any prognostic value in our cohort, our molecular data may add adjunctive discriminatory features for diagnostic purposes on a molecular level.
Introduction: Large-cell transformation (LCT) of mycosis fungoides (MF) has been associated with a higher risk of relapse and progression and, consequently, restricted prognosis. Its molecular pathogenesis has not been elucidated yet. Materials and Methods: In order to address molecular mechanisms of LCT, we performed hybrid capture panel-based sequencing of skin biopsies from 10 patients suffering from MF with LCT versus 17 patients without LCT including follow-up biopsies during clinical course, respectively (51 samples in total). The analyzed patients were attributed to three different groups based on the presence of LCT and clinical behavior. Results: While indolent MF cases without LCT did not show pathogenic driver mutations, a high rate of oncogenic alterations was detected in patients with LCT and aggressive clinical courses. Various genes of different oncogenic signaling pathways, including the MAPK and JAK-STAT signaling pathways, as well as epigenetic modifiers were affected. A high inter-individual and distinctive intra-individual mutation diversity was observed. Oncogenic RAS mutations were exclusively detected in patients with LCT. Conclusion: Our data demonstrate that LCT transition of MF is associated with increased frequency of somatic mutations in cancer-associated genes. In particular, the activation of RAS signaling — together with epigenetic dysregulation — may crucially contribute to the molecular pathogenesis of the LCT phenotype, thus conveying its adverse clinical behavior.
The Proteome Profiles of the Cerebellum of Juvenile, Adult and Aged Rats-An Ontogenetic Study
(2015)
In this study, we searched for proteins that change their expression in the cerebellum (Ce) of rats during ontogenesis. This study focuses on the question of whether specific proteins exist which are differentially expressed with regard to postnatal stages of development. A better characterization of the microenvironment and its development may result from these study findings. A differential two-dimensional polyacrylamide gel electrophoresis (2DE) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) analysis of the samples revealed that the number of proteins of the functional classes differed depending on the developmental stages. Especially members of the functional classes of biosynthesis, regulatory proteins, chaperones and structural proteins show the highest differential expression within the analyzed stages of development. Therefore, members of these functional protein groups seem to be involved in the development and differentiation of the Ce within the analyzed development stages. In this study, changes in the expression of proteins in the Ce at different postnatal developmental stages (postnatal days (P) 7, 90, and 637) could be observed. At the same time, an identification of proteins which are involved in cell migration and differentiation was possible. Especially proteins involved in processes of the biosynthesis and regulation, the dynamic organization of the cytoskeleton as well as chaperones showed a high amount of differentially expressed proteins between the analyzed dates.
The proteome profiles of the olfactory bulb of juvenile, adult and aged rats - an ontogenetic study
(2015)
Background:
In this study, we searched for proteins that change their expression in the olfactory bulb (oB) of rats during ontogenesis. Up to now, protein expression differences in the developing animal are not fully understood. Our investigation focused on the question whether specific proteins exist which are only expressed during different development stages. This might lead to a better characterization of the microenvironment and to a better determination of factors and candidates that influence the differentiation of neuronal progenitor cells.
Results:
After analyzing the samples by two-dimensional polyacrylamide gel electrophoresis (2DE) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS), it could be shown that the number of expressed proteins differs depending on the developmental stages. Especially members of the functional classes, like proteins of biosynthesis, regulatory proteins and structural proteins, show the highest differential expression in the stages of development analyzed.
Conclusion:
In this study, quantitative changes in the expression of proteins in the oB at different developmental stages (postnatal days (P) 7, 90 and 637) could be observed. Furthermore, the expression of many proteins was found at specific developmental stages. It was possible to identify these proteins which are involved in processes like support of cell migration and differentiation.
Current guidelines recommend consolidation with autologous stem cell transplantation (autoSCT) after induction chemotherapy for most patients with peripheral T-cell lymphoma (PTCL). This assumption is based on five prospective phase II studies, three of which included <50 patients with limited follow-up. Here we present the final analysis of the prospective German study. The treatment regimen consisted of four to six cycles of CHOP chemotherapy followed by mobilizing therapy and stem cell collection. Patients in complete remission (CR) or partial remission (PR) underwent myeloablative chemo(radio)therapy and autoSCT. From January 2001 to July 2010, 111 patients were enrolled in the study. The main subgroups were PTCL not specified (n=42) and angioimmunoblastic T-cell lymphoma (n=37). Seventy-five (68%) of the 111 patients received transplantation. The main reason for not receiving autoSCT was progressive disease. In an intent-to-treat analysis, the complete response rate after myeloablative therapy was 59%. The estimated 5-year overall survival, disease-free survival and progression-free survival rates were 44%, 54% and 39%, respectively. The results of this study confirm that upfront autoSCT can result in long-term remissions in patients with all major subtypes of PTCL and therefore should be part of first-line therapy whenever possible.
Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging
(2015)
Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [\(^{68}\)Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [\(^{68}\)Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [\(^{68}\)Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [\(^{68}\)Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.
C-X-C motif chemokine receptor 4 (CXCR4) and somatostatin receptors (SSTR) are overexpressed in gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). In this study, we aimed to elucidate the feasibility of non-invasive CXCR4 positron emission tomography/computed tomography (PET/CT) imaging in GEP-NET patients using [\(^{68}\)Ga]Pentixafor in comparison to \(^{68}\)Ga-DOTA-D-Phe-Tyr3-octreotide ([\(^{68}\)Ga]DOTATOC) and \(^{18}\)F-fluorodeoxyglucose ([\(^{18}\)F]FDG). Twelve patients with histologically proven GEP-NET (3xG1, 4xG2, 5xG3) underwent [\(^{68}\)Ga]DOTATOC, [\(^{18}\)F]FDG, and [\(^{68}\)Ga]Pentixafor PET/CT for staging and planning of the therapeutic management. Scans were analyzed on a patient as well as on a lesion basis and compared to immunohistochemical staining patterns of CXCR4 and somatostatin receptors SSTR2a and SSTR5. [\(^{68}\)Ga]Pentixafor visualized tumor lesions in 6/12 subjects, whereas [\(^{18}\)F]FDG revealed sites of disease in 10/12 and [\(^{68}\)Ga]DOTATOC in 11/12 patients, respectively. Regarding sensitivity, SSTR-directed PET was the superior imaging modality in all G1 and G2 NET. CXCR4-directed PET was negative in all G1 NET. In contrast, 50% of G2 and 80% of G3 patients exhibited [\(^{68}\)Ga]Pentixafor-positive tumor lesions. Whereas CXCR4 seems to play only a limited role in detecting well-differentiated NET, increasing receptor expression could be non-invasively observed with increasing tumor grade. Thus, [\(^{68}\)Ga]Pentixafor PET/CT might serve as non-invasive read-out for evaluating the possibility of CXCR4-directed endoradiotherapy in advanced dedifferentiated SSTR-negative tumors.
Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines
(2020)
Approximately 20% of multiple myeloma (MM) cases harbor a point mutation in KRAS. However, there is still no final consent on whether KRAS-mutations are associated with disease outcome. Specifically, no data exist on whether KRAS-mutations have an impact on survival of MM patients at diagnosis in the era of novel agents. Direct blockade of KRAS for therapeutic purposes is mostly impossible, but recently a mutation-specific covalent inhibitor targeting KRAS\(^{p.G12C}\) entered into clinical trials. However, other KRAS hotspot-mutations exist in MM patients, including the less common exon-4 mutations. For the current study, the coding regions of KRAS were deep-sequenced in 80 newly diagnosed MM patients, uniformely treated with three cycles of bortezomib plus dexamethasone and cyclophosphamide (VCD)-induction, followed by high-dose chemotherapy and autologous stem cell transplantation. Moreover, the functional impact of KRAS\(^{p.G12A}\) and the exon-4 mutations p.A146T and p.A146V on different survival pathways was investigated. Specifically, KRAS\(^{WT}\), KRAS\(^{p.G12A}\), KRAS\(^{p.A146T}\), and KRAS\(^{p.A146V}\) were overexpressed in HEK293 cells and the KRAS\(^{WT}\) MM cell lines JJN3 and OPM2 using lentiviral transduction and the Sleeping Beauty vector system. Even though KRAS-mutations were not correlated with survival, all KRAS-mutants were found capable of potentially activating MEK/ERK- and sustaining PI3K/AKT-signaling in MM cells.
The treatment of Parkinson's disease by transplantation of dopaminergic (DA) neurons from human embryonic mesencephalic tissue is a promising approach. However, the origin of these cells causes major problems: availability and standardization of the graft. Therefore, the generation of unlimited numbers of DA neurons from various types of stem or progenitor cells has been brought into focus. A source for DA neurons might be conditionally immortalized progenitor cells. The temperature-sensitive immortalized cell line CSM14.1 derived from the mesencephalon of an embryonic rat has been used successfully for transplantation experiments. This cell line was analyzed by unbiased stereology of cell type specific marker proteins and 2D-gel electrophoresis followed by mass spectrometry to characterize the differentially expressed proteome. Undifferentiated CSM14.1 cells only expressed the stem cell marker nestin, whereas differentiated cells expressed GFAP or NeuN and tyrosine hydroxylase. An increase of the latter cells during differentiation could be shown. By using proteomics an explanation on the protein level was found for the observed changes in cell morphology during differentiation, when CSM14.1 cells possessed the morphology of multipolar neurons. The results obtained in this study confirm the suitability of CSM14.1 cells as an in vitro model for the study of neuronal and dopaminergic differentiation in rats.
Somatic mutations in protein kinase A catalytic α subunit (PRKACA) were found to be causative for 30-40% of cortisol-producing adenomas (CPA) of the adrenal gland, rendering PKA signalling constitutively active. In its resting state, PKA is a stable and inactive heterotetramer, consisting of two catalytic and two regulatory subunits with the latter inhibiting PKA activity. The human genome encodes three different PKA catalytic subunits and four different regulatory subunits that are preferentially expressed in different organs. In normal adrenal glands all regulatory subunits are expressed, while CPA exhibit reduced protein levels of the regulatory subunit IIβ. In this study, we linked for the first time the loss of RIIβ protein levels to the PRKACA mutation status and found the down-regulation of RIIβ to arise post-transcriptionally. We further found the PKA subunit expression pattern of different tumours is also present in the zones of the normal adrenal cortex and demonstrate that the different PKA subunits have a differential expression pattern in each zone of the normal adrenal gland, indicating potential specific roles of these subunits in the regulation of different hormones secretion.
We aimed to elucidate the diagnostic potential of the C-X-C motif chemokine receptor 4 (CXCR4)-directed positron emission tomography (PET) tracer \(^{68}\)Ga-Pentixafor in patients with poorly differentiated neuroendocrine carcinomas (NEC), relative to the established reference standard \(^{18}\)F-FDG PET/computed tomography (CT). In our database, we retrospectively identified 11 treatment-naïve patients with histologically proven NEC, who underwent \(^{18}\)F-FDG and CXCR4-directed PET/CT for staging and therapy planning. The images were analyzed on a per-patient and per-lesion basis and compared to immunohistochemical staining (IHC) of CXCR4 from PET-guided biopsies. \(^{68}\)Ga-Pentixafor visualized tumor lesions in 10/11 subjects, while \(^{18}\)F-FDG revealed sites of disease in all 11 patients. Although weak to moderate CXCR4 expression could be corroborated by IHC in 10/11 cases, \(^{18}\)F-FDG PET/CT detected significantly more tumor lesions (102 vs. 42; total lesions, n = 107; p < 0.001). Semi-quantitative analysis revealed markedly higher 18F-FDG uptake as compared to \(^{68}\)Ga-Pentixafor (maximum and mean standardized uptake values (SUV) and tumor-to-background ratios (TBR) of cancerous lesions, SUVmax: 12.8 ± 9.8 vs. 5.2 ± 3.7; SUVmean: 7.4 ± 5.4 vs. 3.1 ± 3.2, p < 0.001; and, TBR 7.2 ± 7.9 vs. 3.4 ± 3.0, p < 0.001). Non-invasive imaging of CXCR4 expression in NEC is inferior to the reference standard \(^{18}\)F-FDG PET/CT.
TP53 mutations have been associated with anaplasia in Wilms tumour, which conveys a high risk for relapse and fatal outcome. Nevertheless, TP53 alterations have been reported in no more than 60% of anaplastic tumours, and recent data have suggested their presence in tumours that do not fulfil the criteria for anaplasia, questioning the clinical utility of TP53 analysis. Therefore, we characterized the TP53 status in 84 fatal cases of Wilms tumour, irrespective of histological subtype. We identified TP53 alterations in at least 90% of fatal cases of anaplastic Wilms tumour, and even more when diffuse anaplasia was present, indicating a very strong if not absolute coupling between anaplasia and deregulation of p53 function. Unfortunately, TP53 mutations do not provide additional predictive value in anaplastic tumours since the same mutation rate was found in a cohort of non-fatal anaplastic tumours. When classified according to tumour stage, patients with stage I diffuse anaplastic tumours still had a high chance of survival (87%), but this rate dropped to 26% for stages II–IV. Thus, volume of anaplasia or possible spread may turn out to be critical parameters. Importantly, among non-anaplastic fatal tumours, 26% had TP53 alterations, indicating that TP53 screening may identify additional cases at risk. Several of these non-anaplastic tumours fulfilled some criteria for anaplasia, for example nuclear unrest, suggesting that such partial phenotypes should be under special scrutiny to enhance detection of high-risk tumours via TP53 screening. A major drawback is that these alterations are secondary changes that occur only later in tumour development, leading to striking intratumour heterogeneity that requires multiple biopsies and analysis guided by histological criteria. In conclusion, we found a very close correlation between histological signs of anaplasia and TP53 alterations. The latter may precede development of anaplasia and thereby provide diagnostic value pointing towards aggressive disease.
The introduction of new therapeutic agents has revolutionized the treatment of metastatic melanoma. The approval of adjuvant anti‐programmed death‐1 monotherapy with nivolumab or pembrolizumab, and dabrafenib plus trametinib has recently set a new landmark in the treatment of stage III melanoma. Now, clinical trials have shown that immune checkpoint blockade can be performed in a neoadjuvant setting, an approach established as a standard therapeutic approach for other tumour entities such as breast cancer. Recent studies suggest that a pathological response achieved by neoadjuvant immunotherapy is associated with long‐term tumour control and that short neoadjuvant application of checkpoint inhibitors may be superior to adjuvant therapy. Most recently, neoadjuvant ipilimumab plus nivolumab in stage III melanoma was reported. With two courses of dose‐optimized ipilimumab (1 mg kg−1) combined with nivolumab (3 mg kg−1), pathological responses were observed in 77% of patients, while only 20% of patients experienced grade 3 or 4 adverse events. However, the neoadjuvant trials employing combined immune checkpoint blockade conducted so far have excluded patients with in transit metastases, a common finding in stage III melanoma. Here we report four patients with in transit metastases or an advanced primary tumour who have been treated with neoadjuvant ipilimumab plus nivolumab according to the OpACIN‐neo trial scheme (arm B). All patients achieved radiological disease control and a pathological response. None of the patients has relapsed so far.
Due to the rapidly increasing development and use of cellular products, there is a rising demand for non-animal-based test platforms to predict, study and treat undesired immunity. Here, we generated human organotypic skin models from human biopsies by isolating and expanding keratinocytes, fibroblasts and microvascular endothelial cells and seeding these components on a collagen matrix or a biological vascularized scaffold matrix in a bioreactor. We then were able to induce inflammation-mediated tissue damage by adding pre-stimulated, mismatched allogeneic lymphocytes and/or inflammatory cytokine-containing supernatants histomorphologically mimicking severe graft versus host disease (GvHD) of the skin. This could be prevented by the addition of immunosuppressants to the models. Consequently, these models harbor a promising potential to serve as a test platform for the prediction, prevention and treatment of GvHD. They also allow functional studies of immune effectors and suppressors including but not limited to allodepleted lymphocytes, gamma-delta T cells, regulatory T cells and mesenchymal stromal cells, which would otherwise be limited to animal models. Thus, the current test platform, developed with the limitation that no professional antigen presenting cells are in place, could greatly reduce animal testing for investigation of novel immune therapies.
Epstein-Barr virus (EBV) is best known for infection of B cells, in which it usually establishes an asymptomatic lifelong infection, but is also associated with the development of multiple B cell lymphomas. EBV also infects epithelial cells and is associated with all cases of undifferentiated nasopharyngeal carcinoma (NPC). EBV is etiologically linked with at least 8% of gastric cancer (EBVaGC) that comprises a genetically and epigenetically distinct subset of GC. Although we have a very good understanding of B cell entry and lymphomagenesis, the sequence of events leading to EBVaGC remains poorly understood. Recently, ephrin receptor A2 (EPHA2) was proposed as the epithelial cell receptor on human cancer cell lines. Although we confirm some of these results, we demonstrate that EBV does not infect healthy adult stem cell-derived gastric organoids. In matched pairs of normal and cancer-derived organoids from the same patient, EBV only reproducibly infected the cancer organoids. While there was no clear pattern of differential expression between normal and cancer organoids for EPHA2 at the RNA and protein level, the subcellular location of the protein differed markedly. Confocal microscopy showed EPHA2 localization at the cell-cell junctions in primary cells, but not in cancer cell lines. Furthermore, histologic analysis of patient tissue revealed the absence of EBV in healthy epithelium and presence of EBV in epithelial cells from inflamed tissue. These data suggest that the EPHA2 receptor is not accessible to EBV on healthy gastric epithelial cells with intact cell-cell contacts, but either this or another, yet to be identified receptor may become accessible following cellular changes induced by inflammation or transformation, rendering changes in the cellular architecture an essential prerequisite to EBV infection.
Background:
Conventional parameters including Ki67, hormone receptor and Her2/neu status are used for risk stratification for breast cancer. The serine protease urokinase plasminogen activator (uPA) and the plasminogen activator inhibitor type-1 (PAI-1) play an important role in tumour invasion and metastasis. Increased concentrations in tumour tissue are associated with more aggressive potential of the disease. Multigene tests provide detailed insights into tumour biology by simultaneously testing several prognostically relevant genes. With OncotypeDX\(^{®}\), a panel of 21 genes is tested by means of quantitative real-time polymerase chain reaction.
The purpose of this pilot study was to analyse whether a combination of Ki67 and uPA/PAI-1 supplies indications of the result of the multigene test.
Methods:
The results of Ki67, uPA/PAI-1 and OncotypeDX\(^{®}\) were analysed in 25 breast carcinomas (luminal type, pT1/2, max pN1a, G2). A statistical and descriptive analysis was performed.
Results:
With a proliferation index Ki67 of < 14%, the recurrence score (RS) from the multigene test was on average in the low risk range, with an intermediate RS usually resulting if Ki67 was > 14%. Not elevated values of uPA and PAI-1 showed a lower rate of proliferation (average 8.5%) than carcinomas with an increase of uPA and/or PAI-1 (average 13.9%); p = 0.054, Student’s t-test. When Ki67 was > 14% and uPA and/or PAI-1 was raised, an intermediate RS resulted. These differences were significant when compared to cases with Ki67 < 14% with non-raised uPA/PAI-1 (p < 0.03, Student’s t-test). Without taking into account the proliferative activity, an intermediate RS was also verifiable if both uPA and PAI-1 showed raised values.
Conclusion:
A combination of the values Ki67 and uPA/PAI-1 tended to depict the RS to be expected. From this it can be deduced that an appropriate analysis of this parameter combination may be undertaken before the multigene test in routine clinical practice. The increasing cost pressure makes it necessary to base the implementation of a multigene test on ancillary variables and to potentially leave it out if not required in the event of a certain constellation of results (Ki67 raised, uPA and PAI-1 raised).